Functional imaging in primary tumour‐induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor‐based functional scans: a series of nine patients

Abstract

In patients with pTIO, the somatostatin receptor-based functional scans performed better than (18) F-FDG PET/CT in tumour localization. Amongst the somatostatin receptor-based scans, (99) Tc-HYNIC-TOC SPECT/CT and (68) Ga-DOTATATE PET/CT performed equally well for localization of tumours.

Tumor-associated FGF-23-induced hypophosphatemic rickets in children: a case report and review of the literature

“…Recent papers confirm a good sensitivity of SSTR-based functional scans [11] and superiority to [ 18 F]-Fludeoxyglucose ([ 18 F]-FDG) and PET computed tomography (CT) scan in localizing the respective tumors [12]. Furthermore, measurement of FGF-23 plasma levels shows analytical and biological variability, complicating the interpretation of results [13].…”

Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients

“…c Axial CT image of the pelvis shows a sclerotic focus in the greater trochanter of the right femur, which corresponds to the aforementioned tracer avidity on the Ga68-DOTA peptide PET/CT advanced primary hyperparathyroidism. If the condition develops before growth plate closure, it can present with skeletal deformities, growth retardation and gait problems and even rickets in children [1,10].…”

“…Localization of TIO lesions is however a challenging task as these lesions are usually very small in size and frequently undetectable on clinical examinations [10]. It can be situated in the bone or soft tissue anywhere in the body from head to toe.…”

“…Some authors advocate F18-fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography (FDG-PET/CT) for localizing TIO [5,10]. While FDG-PET/CT may be very sensitive, it is non-specific and may identify areas of increased metabolic activity that are not related to the tumor [5].…”

“…Another important imaging modality is 111-indium octreotide scintigraphy, ideally combined with single photon emission CT (SPECT) [4,10]. Somatostatin receptors have been found to be present in many TIO lesions, and 111-indium octreotide has a high affinity for the somatostatin receptor, especially subtype 2 and to a lesser extent subtype 5 [13,15].…”